Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 5/20 | 0.41 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20299758 | 0.87 | HSD11B1 (0.48) | CCR5HTR2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26910204 | 0.84 | CHRM5 (0.44) | CHRM2CHRM5CHRM1CHRM3CCR5 | |
| SCHEMBL4807302 | 0.78 | PTGDR2 (0.46) | CHRM2CHRM5CHRM1CHRM3CCR5 | |
| SCHEMBL4807309 | 0.78 | PTGDR2 (0.46) | CHRM2CHRM5CHRM1CHRM3CCR5 | |
| SCHEMBL17956550 | 0.76 | AGTR2 (0.39) | CHRM2CHRM5CHRM1CHRM3NPC1 | |
| SCHEMBL20780570 | 0.75 | HTR2A (0.65) | HTR2A | |
| SCHEMBL6202628 | 0.74 | HTR2A (0.51) | CHRM3HTR2A | |
| SCHEMBL803784 | 0.74 | CCR5 (0.45) | CHRM2CHRM5CHRM1CHRM3CCR5 | |
| SCHEMBL26966069 | 0.74 | HSD11B1 (0.52) | AGTR2HSD11B1 | |
| SCHEMBL17956403 | 0.74 | ACE (0.35) | CHRM2CHRM5CHRM1CHRM3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558980-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C N C C S S C A R L COLLEZIONE NAZ DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2021-01-27 | — | — | EP | disclosed |
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-10-27 | — | — | US | disclosed |
| US-20200095232-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C.N.C.C.S. S.C.A.R.L. COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENING (IT) | 2020-03-26 | — | — | US | disclosed |
| EP-3558980-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (IT) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018115275-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | IRBM SCIENCE PARK S.P.A. (IT) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815222-B2 | Compounds for use in the treatment of kinetoplastid infection | NISCH, TK2, FDPS | CHRM2 3505/4885CHRM5 2907/4885CHRM1 3625/4885 |
| US-20200095232-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF KINETOPLASTID INFECTION | NISCH, TK2, FDPS | CHRM2 3505/4885CHRM5 2907/4885CHRM1 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.